Eszopiclone oral film - IntelGenx

Drug Profile

Eszopiclone oral film - IntelGenx

Alternative Names: INT 0020/2010; INT-0020

Latest Information Update: 27 Feb 2014

Price : $50

At a glance

  • Originator IntelGenx Corp.
  • Class 2 ring heterocyclic compounds; Esters; Hypnosedatives; Piperazines; Pyrazines; Pyridines; Pyrroles; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Insomnia

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 27 Feb 2014 Development of eszopiclone oral film is ongoing in Insomnia
  • 06 Apr 2011 IntelGenx completes a phase I trial in Healthy volunteers in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top